MISSISSAUGA, ON, Dec. 4, 2018 /CNW/ - Cipher Pharmaceuticals Inc. (TSX:CPH) ("Cipher" or "the Company") today announced that pharmaceutical industry commercial executive, Michael Milloy, has joined the Company in the position of Vice President, Canadian Commercial Operations. Mr. Milloy has more than 20 years of pharmaceutical industry experience in the commercialization of pharmaceutical products.
Prior to joining Cipher, Mr. Milloy, held the position of Business Unit Head, Neurology & Immunology with EMD Serono, where he was responsible for the executive leadership and strategic direction to a business unit growing at an annual growth rate of 30%. Prior to working at EMD Serono, Mr. Milloy held senior positions at Biogen Canada and Takeda Canada.
"We are pleased to welcome Michael to the leadership team at Cipher," said Robert Tessarolo, President and CEO of Cipher. "Michael has a proven track record of commercial leadership and extensive background in optimizing execution and launch readiness across all components of Sales, Strategy, Marketing, Patient Services, Market Access, Training and New Product Planning. Michael will be a valuable addition to the team as we launch new products into the Canadian market."
"I'm excited to join Cipher at this important stage in the Company's growth," added Mr. Milloy. "Cipher has multiple current and future product launches, and I look forward to bringing these innovate products to Canadian patients."
Mr. Milloy holds a BA Psychology, BSc Biology and an Executive MBA with a specialty in General Management.
Certain statements in this release constitute forward-looking statements within the meaning of applicable securities laws. Forward-looking statements in this press release include, without limitation, statements relating to: the anticipated strategic and/or financial benefits of the arrangement to Cipher; and anticipated regulatory approvals of products and the anticipated timing thereof. Words such as "may", "would", "could", "should", "will", "anticipate", "believe", "plan", "expect", "intend", "potential" and similar expressions may be used to identify these forward-looking statements although not all forward-looking statements contain such words.
Forward-looking statements involve significant risks, uncertainties and assumptions. Many factors could cause actual results, performance or achievements to be materially different from any future results, performance or achievements that may be expressed or implied by such forward-looking statements, including risks associated with acquisitions generally, such as: completion of the acquisition may be prove to be more costly than expected; the inability of Cipher to successfully integrate the acquired business and products; Cipher may not obtain anticipated regulatory approvals in respect of certain products or such approvals may take longer than anticipated; inability of Cipher to achieve the anticipated strategic and/or financial benefits from the acquisition or it may take longer than expected to achieve those benefits; and the risk of unexpected costs or liabilities relating to the acquisition. Further, additional risk factors that could cause actual results to differ materially from expectations can be found in the "Risk Factors" section of Cipher's Annual Information Form and in Cipher's Management's Discussion and Analysis of Operating Results and Financial Position for the year ended December 31, 2017 and/or for the three and nine months ended September 30, 2018, and elsewhere in Ciphers's filings with Canadian securities regulators.
Should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward-looking statements prove incorrect, actual results, performance or achievements may vary materially from those expressed or implied by this press release. These factors should be considered carefully and reader should not place undue reliance on the forward-looking statements. These forward-looking statements are made as of the date of this press release and, other than as required by law, Cipher does not intend to or assume any obligation to update or revise these forward-looking statements, whether as a result of new information, future events or otherwise.
About Cipher Pharmaceuticals Inc.
Cipher (TSX:CPH) is a specialty pharmaceutical company with a robust and diversified portfolio of commercial and early to late-stage products. Cipher acquires products that fulfill unmet medical needs, manages the required clinical development and regulatory approval process, and markets those products either directly in Canada or indirectly through partners in Canada, the U.S., and South America. Cipher is focused on a three-pronged growth strategy – including acquisitions, in-licensing, and selective investments in drug development – to assemble a broad portfolio of prescription products that serve unmet medical needs. For more information, visit www.cipherpharma.com.
SOURCE Cipher Pharmaceuticals Inc.
For further information: Stefan Eftychiou, Bristol Investor Relations, (905) 326-1888 ext. 60, [email protected]